| Foreword |
|
vii | |
|
|
| Foreword |
|
ix | |
|
|
| Acknowledgements |
|
xi | |
|
|
|
1 | (12) |
|
What it really means to be `controversial' |
|
|
5 | (5) |
|
Our collaboration with the media |
|
|
10 | (3) |
|
2 Important issues in cancer screening |
|
|
13 | (16) |
|
What it means `to have cancer' |
|
|
13 | (2) |
|
Overdiagnosis and overtreatment |
|
|
15 | (1) |
|
Erroneous diagnoses and carcinoma in situ |
|
|
16 | (3) |
|
Basic issues in cancer epidemiology |
|
|
19 | (1) |
|
Randomised trials, observational studies and a little statistics |
|
|
20 | (2) |
|
Why screening leads to misleading survival statistics |
|
|
22 | (1) |
|
Why 10-year survival is also misleading |
|
|
23 | (6) |
|
3 Does screening work in Sweden? |
|
|
29 | (5) |
|
4 Stonewalling the Cochrane report on screening |
|
|
34 | (12) |
|
The Danish National Board of Health interferes with our report |
|
|
40 | (6) |
|
5 Troubling results in the Lancet |
|
|
46 | (27) |
|
|
|
50 | (2) |
|
|
|
52 | (3) |
|
|
|
55 | (1) |
|
Our collaboration with the trialists |
|
|
56 | (2) |
|
Ten letters to the editor |
|
|
58 | (2) |
|
Creative manipulations in Sweden |
|
|
60 | (3) |
|
Peter Dean, a remarkable character |
|
|
63 | (3) |
|
Bad manners also in Norway |
|
|
66 | (2) |
|
Continued troubles in Denmark |
|
|
68 | (5) |
|
6 Harms dismissed by the Cochrane Breast Cancer Group |
|
|
73 | (12) |
|
The process with the Cochrane review |
|
|
75 | (2) |
|
|
|
77 | (1) |
|
Confusion over who is in charge |
|
|
78 | (7) |
|
7 The Lancet publishes the harms of screening |
|
|
85 | (18) |
|
Vitriolic mass email from Peter Dean |
|
|
90 | (3) |
|
Beating about the bush in the United Kingdom |
|
|
93 | (2) |
|
|
|
95 | (4) |
|
Contempt of science in Denmark and Norway |
|
|
99 | (4) |
|
8 Delayed media storm in the United States after our 2001 reviews |
|
|
103 | (11) |
|
Miettinen and Henschke's cherry-picking in the Lancet |
|
|
107 | (1) |
|
Additional reactions in the United States |
|
|
108 | (6) |
|
9 The Danish National Board of Health circles the wagons |
|
|
114 | (6) |
|
10 US and Swedish 2002 meta-analyses |
|
|
120 | (6) |
|
US Preventive Services Task Force's meta-analysis |
|
|
120 | (1) |
|
Nystrom's updated Swedish meta-analysis |
|
|
121 | (5) |
|
11 Scientific debates in the United States |
|
|
126 | (10) |
|
Peter Dean is wrong again |
|
|
126 | (4) |
|
Multiple errors in the International Journal of Epidemiology |
|
|
130 | (6) |
|
12 Publication of entire Cochrane review obstructed for 5 years |
|
|
136 | (11) |
|
Cochrane editors stonewall our Cochrane review |
|
|
138 | (5) |
|
|
|
143 | (2) |
|
Welcome results in France |
|
|
145 | (2) |
|
13 Editorial misconduct in the European Journal of Cancer |
|
|
147 | (16) |
|
|
|
151 | (4) |
|
Threats, intimidation and falsehoods |
|
|
155 | (3) |
|
Debates in the Scientist and the Cancer Letter |
|
|
158 | (5) |
|
14 Tabar's `beyond reason' studies |
|
|
163 | (10) |
|
Criticism of our work in the Journal of Surgical Oncology |
|
|
168 | (5) |
|
15 Other observational studies of breast cancer mortality |
|
|
173 | (12) |
|
The United States and the United Kingdom |
|
|
174 | (1) |
|
Denmark, Lynge's 2005 study |
|
|
175 | (2) |
|
|
|
177 | (8) |
|
16 Overdiagnosis and overtreatment |
|
|
185 | (35) |
|
Cancers that regress spontaneously |
|
|
186 | (2) |
|
The 1986 UK Forrest report |
|
|
188 | (1) |
|
Overdiagnosis in the randomised trials |
|
|
189 | (5) |
|
Systematic review of overdiagnosis in observational studies |
|
|
194 | (6) |
|
Observational studies from Denmark and New South Wales |
|
|
200 | (2) |
|
|
|
202 | (3) |
|
Duffy's studies on overdiagnosis |
|
|
205 | (2) |
|
Lynge's studies on overdiagnosis |
|
|
207 | (3) |
|
Carcinoma in situ and the increase in mastectomies |
|
|
210 | (10) |
|
17 Ad hominem attacks: a measure of desperation? |
|
|
220 | (18) |
|
UK statistician publishes in Danish |
|
|
222 | (1) |
|
Inappropriate name-dropping |
|
|
223 | (3) |
|
Further ad hominem arguments |
|
|
226 | (1) |
|
Lynge's unholy mixture of politics and science |
|
|
227 | (3) |
|
Ad hominem attacks ad infinitum |
|
|
230 | (8) |
|
18 US recommendations for women aged 40-49 years |
|
|
238 | (7) |
|
19 What have women been told? |
|
|
245 | (34) |
|
Website information on screening |
|
|
245 | (2) |
|
|
|
247 | (5) |
|
A scandalous revision of the Danish screening leaflet |
|
|
252 | (2) |
|
|
|
254 | (1) |
|
Breast screening: the facts, or maybe not |
|
|
255 | (7) |
|
|
|
262 | (5) |
|
Information from other cancer societies |
|
|
267 | (4) |
|
Getting funding or not getting funding |
|
|
271 | (1) |
|
|
|
272 | (7) |
|
20 Extraordinary exaggerations |
|
|
279 | (19) |
|
What is the ratio between benefits and harms? |
|
|
280 | (2) |
|
|
|
282 | (5) |
|
|
|
287 | (5) |
|
The exaggerations finally backfire |
|
|
292 | (2) |
|
The ultimate exaggeration |
|
|
294 | (4) |
|
21 Tabar threatens the BMJ with litigation |
|
|
298 | (8) |
|
22 Falsehoods and perceived censorship in Sweden |
|
|
306 | (5) |
|
23 Celebrating 20 years of breast screening in the United Kingdom |
|
|
311 | (9) |
|
|
|
320 | (11) |
|
Plausible effect based on tumour sizes in the trials |
|
|
320 | (3) |
|
|
|
323 | (1) |
|
Plausible effect based on tumour stages in the trials |
|
|
324 | (2) |
|
No decrease in advanced cancers |
|
|
326 | (5) |
|
25 Where is screening at today? |
|
|
331 | (16) |
|
Problems with reading mammograms |
|
|
332 | (1) |
|
|
|
333 | (3) |
|
Important information is being ignored |
|
|
336 | (2) |
|
Beliefs warp evidence at conferences |
|
|
338 | (2) |
|
Does breast screening make women live longer? |
|
|
340 | (7) |
|
|
|
347 | (16) |
|
|
|
351 | (1) |
|
A press release from Radiology that wasn't |
|
|
352 | (1) |
|
Has all my struggle achieved anything? |
|
|
353 | (4) |
|
Why has so much evidence about screening been distorted? |
|
|
357 | (1) |
|
Time to stop breast cancer screening |
|
|
358 | (5) |
| Appendix 1 Tabar's explanations in the Cancer Letter and our replies |
|
363 | (6) |
| Appendix 2 Our 2008 mammography screening leaflet |
|
369 | (12) |
| Appendix 3 The press release Radiology withdrew at the last minute |
|
381 | (3) |
| Index |
|
384 | |